# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Edward White reiterates Dynavax Technologies (NASDAQ:DVAX) with a Buy and maintains $29 pric...
HC Wainwright & Co. analyst Edward White reiterates Dynavax Technologies (NASDAQ:DVAX) with a Buy and maintains $29 pric...
Latest regulatory update from Dynavax on HEPLISAV-B vaccine regimen for adults on hemodialysis, with FDA's Complete Respons...
HC Wainwright & Co. analyst Edward White reiterates Dynavax Technologies (NASDAQ:DVAX) with a Buy and maintains $29 pric...
HEPLISAV-B net product revenue between approximately $265 - $280 million, including approximately $3 million in ex-U.S. sales...
Dynavax Technologies (NASDAQ:DVAX) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate o...